<DOC>
	<DOCNO>NCT00746317</DOCNO>
	<brief_summary>This phase I trial study safety best dose GC33 patient advance metastatic liver cancer .</brief_summary>
	<brief_title>A Phase I Study GC33 Advanced Metastatic Liver Cancer ( Hepatocellular Carcinoma )</brief_title>
	<detailed_description>This Phase I open-label dose escalation study GC33 patient advance metastatic HCC . This study design evaluate safety , tolerability , pharmacokinetics , preliminary assessment anti-tumor activity . Enrollment proceed maximum tolerate dose ( MTD ) recommend Phase II dose establish .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Signed write Institutional Review Board ( IRB ) /Ethical Committee ( EC ) approve informed consent form Male female ≥ 18 year old . Life expectancy ≥ 3 month . ECOG Performance Status 01 . Histologically confirm hepatocellular carcinoma ( without fibrolamellar subtype ) . Not candidate curative treatment . ChildPugh A B. Hematological , Biochemical Organ Function : AST ( SGOT ) : ≤ 5.0 × ULN ALT ( SGPT ) : ≤ 5.0 × ULN Total Bilirubin : ≤ 3.0 × ULN Platelets : ≥ 50,000/μL Absolute Neutrophil Count : ≥ 1,500/μL Serum creatinine : ≤ 2.0 × ULN PTINR : ≤ 2.0 , Ability provide tumor tissue sample either : sample obtain within 3 month prior inform consent HCC diagnosis . Resection sample acceptable . undergo biopsy confirm HCC diagnosis At least one measurable lesion base Response Evaluation Criteria In Solid Tumors criterion . ( Extension Phase ) Signed write Institutional Review Board ( IRB ) /Ethical Committee ( EC ) approve informed consent form . Male female ≥ 18 year old . Life expectancy ≥ 3 month . ECOG Performance Status 01 . Histologically confirm hepatocellular carcinoma ( without fibrolamellar subtype ) . Not candidate curative treatment . ChildPugh A. Hematological , Biochemical Organ Function : AST ( SGOT ) : ≤ 5.0 × ULN ALT ( SGPT ) : ≤ 5.0 × ULN Total Bilirubin : ≤ 3.0 × ULN Platelets : ≥ 50,000/μL Absolute Neutrophil Count : ≥ 1,500/μL Serum creatinine : ≤ 2.0 × ULN PTINR : ≤ 2.0 IHC confirm GPC3positive HCC tumor tissue . Tumor tissue sample may provide : A formalin fix paraffin embed block sample within 12 month prior inform consent HCC diagnosis ; Unstained slide obtain within 3 month prior inform consent HCC diagnosis ; Undergo biopsy confirm GPC3positive HCC . Resection sample acceptable . At least one measurable lesion base Response Evaluation Criteria In Solid Tumors criterion . ChildPugh C. Pregnant lactate woman woman childbearing potential men childbearing potential willing use effective mean contraception . Patients know positive Human immunodeficiency virus infection . Active infectious disease require treatment except hepatitis B C. Other malignancy within last 5 year . History transplantation ( organ , bone marrow transplantation , peripheral blood stem cell transplantation , etc. ) . Patients significant concomitant disease determine investigator potentially aggravate investigational drug . Patients brain metastasis , central nervous system psychiatric disease . Patients receive major surgery , local therapy HCC , chemotherapy , radiotherapy , hormonetherapy , immunotherapy , another investigational drug within 4 week prior Day 1 . Patients receive follow treatment within 2 week prior Day1 : Anticoagulant thrombolytic agent therapeutic purpose . Systemic antiviral therapy hepatitis C/cirrhosis . Blood transfusion History hypersensitivity similar agent . Patient unable comply requirement protocol and/or followup procedure . ( Extension Phase ) ChildPugh B C. Pregnant lactate woman woman childbearing potential men childbearing potential willing use effective mean contraception . Patients know positive Human immunodeficiency virus infection . Active infectious disease require treatment except hepatitis B C. Other malignancy within last 5 year . History transplantation ( organ , bone marrow transplantation , Peripheral blood stem cell transplantation , etc. ) . Patients significant concomitant disease determine investigator potentially aggravate investigational drug . Patients brain metastasis , central nervous system psychiatric disease . Patients receive major surgery , local therapy HCC , chemotherapy , radiotherapy , hormonetherapy , immunotherapy , another investigational drug within 4 week prior Day 1 . Patients receive follow treatment within 2 week prior Day 1 : Anticoagulations thrombolytic agent therapeutic purpose . Systemic antiviral therapy hepatitis C/cirrhosis . Blood transfusion History hypersensitivity similar agent . Patient unable comply requirement protocol and/or followup procedure . IHC confirm GPC3negative HCC tumor tissue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>